FranceTuberculosis profile
Population  2014 64 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.37 (0.36–0.39) 0.58 (0.56–0.61)
Mortality (HIV+TB only) 0.062 (0.034–0.099) 0.1 (0.05–0.15)
Prevalence  (includes HIV+TB) 7.4 (3.5–13) 12 (5.5–20)
Incidence  (includes HIV+TB) 5.6 (5.3–6) 8.7 (8.2–9.3)
Incidence (HIV+TB only) 0.34 (0.28–0.42) 0.53 (0.43–0.65)
         
Case detection, all forms (%) 81 (76–86)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.45 (0.24–0.77) 13 (7.4–21)
MDR-TB cases among notified pulmonary
TB cases
15 (8–25) 41 (23–66)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 515   0
Pulmonary, clinically diagnosed 790   0
Extrapulmonary 1 230   0
       
Total new and relapse 4 535    
Previously treated, excluding relapses 310    
Total cases notified 4 845    
Among 4 512 new and relapse cases:
270 (6%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 358 (134%) 332 (107%) 4 235
Laboratory-confirmed RR-/MDR-TB cases     111
Patients started on MDR-TB treatment ***     111
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013    
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-27 Data: www.who.int/tb/data